Cargando…

Live Cell Mass Accumulation Measurement Non-Invasively Predicts Carboplatin Sensitivity in Triple-Negative Breast Cancer Patient-Derived Xenografts

[Image: see text] Prompt and repeated assessments of tumor sensitivity to available therapeutics could reduce patient morbidity and mortality by quickly identifying therapeutic resistance and optimizing treatment regimens. Analysis of changes in cancer cell biomass has shown promise in assessing dru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murray, Graeme F., Turner, Tia H., Leslie, Kevin A., Alzubi, Mohammad A., Guest, Daniel, Sohal, Sahib S., Teitell, Michael A., Harrell, J. Chuck, Reed, Jason
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2018
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312628/ https://www.ncbi.nlm.nih.gov/pubmed/30613814 http://dx.doi.org/10.1021/acsomega.8b02224

Ejemplares similares

Identification of synergistic drug combinations using breast cancer patient-derived xenografts
por: Turner, Tia H., et al.
Publicado: (2020)

Rewiring of the 3D genome during acquisition of carboplatin resistance in a triple-negative breast cancer patient-derived xenograft
por: Dozmorov, Mikhail G., et al.
Publicado: (2023)

Publisher Correction: Rewiring of the 3D genome during acquisition of carboplatin resistance in a triple-negative breast cancer patient-derived xenograft
por: Dozmorov, Mikhail G., et al.
Publicado: (2023)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Separation of breast cancer and organ microenvironment transcriptomes in metastases
por: Alzubi, Mohammad A., et al.
Publicado: (2019)

Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer
por: Rashid, Narmeen S., et al.
Publicado: (2021)

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
por: Lee, Jung-Min, et al.
Publicado: (2017)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models
por: Jacob, Sheeba, et al.
Publicado: (2022)

OR05-02 The IGFBP-3/IGFBP-3 Receptor Axis Is a New Therapeutic Target for Triple Negative Breast Cancer
por: Cai, Qing, et al.
Publicado: (2020)

The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers
por: Moens, Stijn, et al.
Publicado: (2021)

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
por: Singh, Jasmeet Chadha, et al.
Publicado: (2014)

A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin
por: Wu, Rongrong, et al.
Publicado: (2021)

New generation breast cancer cell lines developed from patient-derived xenografts
por: Finlay-Schultz, Jessica, et al.
Publicado: (2020)

Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial
por: Sipos, O., et al.
Publicado: (2021)

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
por: Yardley, D A, et al.
Publicado: (2018)

Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience
por: Vetter, Marcus, et al.
Publicado: (2017)

Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer
por: Abreu de Oliveira, Willy Antoni, et al.
Publicado: (2021)

Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells
por: Zhao, Hui, et al.
Publicado: (2018)

Thioridazine combined with carboplatin results in synergistic inhibition of triple negative breast cancer by targeting cancer stem cells
por: Wang, Yi, et al.
Publicado: (2022)

Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2023)

Live Cell Interferometry Quantifies Dynamics of Biomass Partitioning during Cytokinesis
por: Zangle, Thomas A., et al.
Publicado: (2014)

Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams
por: Cammarata, Francesco P., et al.
Publicado: (2020)

Protein expression profiling of plasma and lungs at different stages of metastatic development in a human triple negative breast cancer xenograft model
por: Tveitarås, Maria K., et al.
Publicado: (2019)

Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft
por: Bharti, Santosh K., et al.
Publicado: (2018)

Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer: A meta-analysis of randomized controlled trials
por: Wang, Li-Yang, et al.
Publicado: (2017)

A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer
por: Ou, Junwen, et al.
Publicado: (2020)

Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial
por: de Pádua Souza, Cristiano, et al.
Publicado: (2023)

Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer
por: Merino, D., et al.
Publicado: (2019)

Stromal integrin α11-deficiency reduces interstitial fluid pressure and perturbs collagen structure in triple-negative breast xenograft tumors
por: Smeland, Hilde Ytre-Hauge, et al.
Publicado: (2019)

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
por: Matossian, Margarite D., et al.
Publicado: (2019)

Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models
por: Park, Hyung Seok, et al.
Publicado: (2019)

Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models
por: Sabol, Rachel A., et al.
Publicado: (2019)

Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma
por: Bousquet, Guilhem, et al.
Publicado: (2014)

Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple-Negative Breast Cancer Xenografts
por: Liao, Ming-juan, et al.
Publicado: (2014)

Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model
por: Saraiva, Sofia M., et al.
Publicado: (2021)

Identification of two cancer stem cell-like populations in triple-negative breast cancer xenografts
por: Nakayama, Jun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5fjschoquetlk817gfbha84v5h